During the past decade, Florida Cancer Institute conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 17 clinical trials were completed, i.e. on average, 566.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 7 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Florida Cancer Institute" #1 sponsor was "US Oncology Research" with 6 trials, followed by "Pfizer" with 5 trials sponsored, "Eisai Inc." with 3 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "National Cancer Institute (NCI)" with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Florida Cancer Institute" #1 collaborator was "Astellas Pharma Inc" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "NRG Oncology" with 3 trials as a collaborator, "Sanofi" with 3 trials as a collaborator and "Medivation, Inc." with 2 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Florida Cancer Institute" are "Non-Small Cell Lung Cancer" (4 trials), "Breast Cancer" (3 trials), "Prostate Cancer" (3 trials), "Metastatic Breast Cancer" (2 trials) and "Advanced, Androgen Receptor Positive Triple Negative Breast Cancer" (1 trials). Many other conditions were trialed in "Florida Cancer Institute" in a lesser frequency.

Most popular intervention types in "Florida Cancer Institute" are "Drug" (31 trials), "Other" (3 trials), "Radiation" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (3 trials), "Bevacizumab" (2 trials), "Capecitabine" (2 trials), "Carboplatin" (2 trials) and "Enzalutamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Florida Cancer Institute" are 24 trials for "All" genders, 5 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Florida Cancer Institute". undefined are not yet recruiting, undefined are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Florida Cancer Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Florida Cancer Institute, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".